Australian Sports Drug Testing Laboratory, National Measurement Institute, North Ryde, NSW, Australia.
Drug Test Anal. 2012 Dec;4(12):951-61. doi: 10.1002/dta.1403. Epub 2012 Sep 17.
Glucocorticoids are listed on the World Anti-Doping Agency (WADA) Prohibited List of substances. The detection of the administration of hydrocortisone and cortisone is complicated by the fact that the human body also produces these steroids naturally. Gas chromatography-combustion-isotope ratio mass spectrometry can be utilized to determine the use of endogenous glucocorticoids by measuring the carbon isotope ratio (CIR) of their resulting metabolites in human urine samples. A comprehensive sample preparation protocol for the analysis of endogenous glucocorticoid urinary metabolites was developed and validated, incorporating the use of high performance liquid chromatography (HPLC) for purification and chemical oxidation for derivatisation. Target compounds were tetrahydrocortisol and tetrahydrocortisone, and 11β-hydroxyetiocholanolone, 11-oxoetiocholanolone and 11β-hydroxyandrosterone, while pregnanediol functioned as the endogenous reference compound. Urine samples from a population of 50 volunteers were analyzed to determine CIR reference limits. Excretion studies of the endogenous glucocorticoid preparation cortisone acetate (25 mg oral) and the dietary supplement adrenosterone (75 mg oral) were conducted with six male individuals. Variable changes in steroid metabolite isotopic composition were found across subjects after administration. The study also revealed that CIR analysis of the major glucocorticoid metabolites tetrahydrocortisol and tetrahydrocortisone is necessary to unambiguously distinguish administration of cortisone and adrenosterone, the former officially restricted to out-of-competition use by athletes, the latter not being restricted at the current time. Moreover, this study reaffirms that CIR methods for the doping control of endogenous steroids should not rely upon a single ERC, as the administration of an appropriate precursor to that ERC could cause complications during analysis.
糖皮质激素被世界反兴奋剂机构(WADA)列入禁用物质清单。由于人体自身也会自然产生这些类固醇,因此检测氢可的松和可的松的使用情况变得复杂。通过测量人尿液样本中其代谢物的碳同位素比值(CIR),可以利用气相色谱-燃烧-同位素比质谱法来确定内源性糖皮质激素的使用情况。开发并验证了一种用于分析内源性糖皮质激素尿代谢物的综合样品制备方案,该方案结合使用高效液相色谱(HPLC)进行纯化和化学氧化进行衍生化。目标化合物为四氢皮质醇和四氢皮质酮,以及 11β-羟基表雄酮、11-氧表雄酮和 11β-羟基雄甾酮,而孕烷二醇则作为内源性参比化合物。分析了 50 名志愿者的尿液样本,以确定 CIR 参考限值。对皮质酮醋酸酯(25mg 口服)和膳食补充剂雄甾酮(75mg 口服)这两种内源性糖皮质激素制剂进行了 6 名男性个体的排泄研究。给药后,发现不同个体的类固醇代谢物同位素组成发生了变化。该研究还表明,有必要对主要糖皮质激素代谢物四氢皮质醇和四氢皮质酮进行 CIR 分析,以明确区分皮质酮和雄甾酮的使用,前者目前仅允许运动员在比赛外使用,后者目前不受限制。此外,本研究再次证实,用于内源性类固醇兴奋剂控制的 CIR 方法不应仅依赖于单个 ERC,因为向该 ERC 适当给药可能会在分析过程中引起并发症。